Carcinoma, Large Cell: Clinical Trials

7 trials for Carcinoma, Large Cell, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 terminated, 2 completed, 1 active not recruiting, 1 unknown. 7 Phase 2, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 27Terminated 3, Completed 2, Active not recruiting 1, Unknown 1
Phase 11Completed 1

Follow Carcinoma, Large Cell: new trials by email Literature Review of Carcinoma, Large Cell trials Research Report on Carcinoma, Large Cell

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
THIO Sequenced With Cemiplimab in Advanced NSCLC
6-Thio-2'-Deoxyguanosine, Cemiplimab - Carcinoma, Non-Small-Cell Lung
Phase 2Active not recruitingMaia Biotechnology2272022-06-082026-09-16
Stereotactic Body Radiotherapy (SBRT) Versus Stereotactic Body Proton Therapy (SBPT)
SBRT (stereotactic body radiotherapy), SBPT (stereotactic body proton therapy) - Non-small-cell Lung Cancer
Phase 2TerminatedM.D. Anderson Cancer Center212012-08-012017-12-07
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
IPI 504 plus Docetaxel, Placebo plus Docetaxel - Non Small Cell Lung Cancer
Phase 2CompletedInfinity Pharmaceuticals, Inc.2262011-05-012014-05-19
A Phase II Clinical Trial of Docetaxel, Oxaliplatin Combination Chemotherapy in Patients With Stage IIIB/IV Non-adenocarcinoma, Non-small Cell Lung Cancer (NSCLC) as Second-line Treatment
Docetaxel, Oxaliplatin - Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous
Phase 2UnknownKorean South West Oncology Group352011-02-012011-12-22
Study of Maintenance Temozolomide Versus Observation in Stable or Responding Stage III/IV Non-Small Cell Lung Cancer Patients (Study P05146)
Temozolomide - Carcinoma, Non-Small-Cell Lung, Adenocarcinoma
Phase 2TerminatedMerck Sharp & Dohme LLC532008-03-042017-06-07
Trial of Motexafin Gadolinium and Pemetrexed (Alimta®) for Second Line Treatment in Patients With Non-Small Cell Lung Cancer
Motexafin gadolinium and pemetrexed - Non-Small Cell Lung Carcinoma
Phase 2TerminatedPharmacyclics LLC.742006-06-012013-10-31
Vaccine Treatment for Advanced Non-Small Cell Lung Cancer
Drug: Hyperacute Lung Cancer Cell Vaccine - Non-small Cell Carcinoma, Adenocarcinoma of Lung
Phase 1 / Phase 2CompletedNewLink Genetics Corporation542003-11-012020-05-28

Narrower conditions

Carcinoma, Non-Small-Cell Lung (7)  ·  Carcinoma, Squamous Cell (7)  ·  Adenocarcinoma (3)  ·  Lung Neoplasms (3)  ·  Adenocarcinoma of Lung (2)  ·  Carcinoma (1)  ·  Recurrence (1)

Broader conditions

Bronchial Neoplasms (7)  ·  Carcinoma, Bronchogenic (7)  ·  Lung Diseases (7)  ·  Neoplasms (7)  ·  Neoplasms by Histologic Type (7)  ·  Neoplasms by Site (7)  ·  Neoplasms, Glandular and Epithelial (7)  ·  Neoplasms, Squamous Cell (7)  ·  Respiratory Tract Diseases (7)  ·  Respiratory Tract Neoplasms (7)  ·  Thoracic Neoplasms (7)  ·  Carcinoma (6)  ·  Lung Neoplasms (4)  ·  Adenocarcinoma (2)  ·  Disease Attributes (1)

Interventions

Docetaxel (2)  ·  Oxaliplatin (1)  ·  Pemetrexed (1)  ·  Radiosurgery (1)  ·  Radiotherapy (1)  ·  Temozolomide (1)  ·  alpha-2'-deoxythioguanosine (1)  ·  cemiplimab (1)  ·  motexafin gadolinium (1)  ·  tanespimycin (1)

Sponsors

Infinity Pharmaceuticals, Inc. (1)  ·  Korean South West Oncology Group (1)  ·  M.D. Anderson Cancer Center (1)  ·  Maia Biotechnology (1)  ·  Merck Sharp & Dohme LLC (1)  ·  NewLink Genetics Corporation (1)  ·  Pharmacyclics LLC. (1)

Countries

United States (5)  ·  Hungary (2)  ·  South Korea (2)  ·  Taiwan (2)  ·  Australia (1)  ·  Bulgaria (1)  ·  Georgia (1)  ·  Poland (1)  ·  Romania (1)  ·  Russia (1)  ·  Turkey (Türkiye) (1)

Top investigators

Arun Rajan, M.D. (1)  ·  Joe Y. Chang, MD, MS, PHD (1)  ·  Martin Edelman, MD (1)  ·  Sang Byung Bae, M.D. (1)  ·  Tess Schmalbach, MD (1)  ·  Victor Zaporojan, MD (1)

Results publications

PMID 25069747

NIH funding

2023 (1), P01CA021239 (1)